Literature DB >> 11506507

Metabolism and growth inhibition of four retinoids in head and neck squamous normal and malignant cells.

I Klaassen1, R H Brakenhoff, S J Smeets, G B Snow, B J Braakhuis.   

Abstract

Isotretinoin (13-cis-retinoic acid, 13cRA) has proven to be active in chemoprevention of head and neck squamous cell carcinoma (HNSCC). Moreover, both all-trans-retinoic acid (ATRA) and 13cRA induce objective responses in oral premalignant lesions. After binding of retinoids to retinoic acid receptors (RARs and RXRs) dimers are formed that are able to regulate the expression of genes involved in growth and differentiation. We compared the metabolism and level of growth inhibition of 13cRA with that of ATRA, 9cRA and retinol in four HNSCC cell lines and normal oral keratinocyte cultures (OKC). These retinoid compounds are known to bind with different affinities to the retinoic acid receptors. We observed that all retinoids were similar with respect to their capacity to induce growth inhibition. One HNSCC line could be ranked as sensitive, one as moderately sensitive and the remaining two were totally insensitive; OKC were moderately sensitive. The rate at which the cells were able to catabolize the retinoid was similar for all compounds. Retinoid metabolism in HNSCC cells resulted in a profile of metabolites that was unique for each retinoid. These metabolic profiles were different in OKC. Our findings indicate that differences in retinoid receptor selectivity of these retinoids do not influence the level of growth inhibition and rate of metabolism. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11506507      PMCID: PMC2364086          DOI: 10.1054/bjoc.2001.1952

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  36 in total

1.  Enhanced turnover of all-trans-retinoic acid and increased formation of polar metabolites in head and neck squamous cell carcinoma lines compared with normal oral keratinocytes.

Authors:  I Klaassen; R H Brakenhoff; S J Smeets; G B Snow; B J Braakhuis
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

2.  Phase I trial of all-trans retinoic acid in patients with treated head and neck squamous carcinoma.

Authors:  S H Park; W C Gray; I Hernandez; M Jacobs; R A Ord; M Sutharalingam; R G Smith; D A Van Echo; S Wu; B A Conley
Journal:  Clin Cancer Res       Date:  2000-03       Impact factor: 12.531

Review 3.  Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells.

Authors:  R Lotan
Journal:  Biochim Biophys Acta       Date:  1980-03-12

4.  Metabolism of all-trans-retinoic acid in hamster liver microsomes: oxidation of 4-hydroxy- to 4-keto-retinoic acid.

Authors:  A B Roberts; L C Lamb; M B Sporn
Journal:  Arch Biochem Biophys       Date:  1980-02       Impact factor: 4.013

Review 5.  Chemoprevention of head and neck cancer.

Authors:  W B Armstrong; F L Meyskens
Journal:  Otolaryngol Head Neck Surg       Date:  2000-05       Impact factor: 3.497

6.  Modulation of retinoic acid receptor function alters the growth inhibitory response of oral SCC cells to retinoids.

Authors:  Q Le; M I Dawson; D R Soprano; K J Soprano
Journal:  Oncogene       Date:  2000-03-09       Impact factor: 9.867

7.  Expression of retinoic acid receptor gamma correlates with retinoic acid sensitivity and metabolism in head and neck squamous cell carcinoma cell lines.

Authors:  I Klaassen; R H Brakenhoff; S J Smeets; G B Snow; B J Braakhuis
Journal:  Int J Cancer       Date:  2001-06-01       Impact factor: 7.396

8.  Retinoid metabolism in spontaneously transformed mouse fibroblasts (Balb/c 3T12-3 cells): enzymatic conversion of retinol to anhydroretinol.

Authors:  P V Bhat; L M De Luca; S Adamo; I Akalovsky; C S Silverman-Jones; G L Peck
Journal:  J Lipid Res       Date:  1979-03       Impact factor: 5.922

9.  Identification of a decarboxylation product of retinoic acid.

Authors:  N L Rockley; B A Halley; E C Nelson
Journal:  Biochim Biophys Acta       Date:  1980-02-07

10.  Biochemical treatment of precancerous oral lesions: the effectiveness of various analogues of retinoic acid.

Authors:  H F Koch
Journal:  J Maxillofac Surg       Date:  1978-02
View more
  6 in total

1.  Mechanism of inhibition of MMTV-neu and MMTV-wnt1 induced mammary oncogenesis by RARalpha agonist AM580.

Authors:  Y Lu; S Bertran; T-A Samuels; R Mira-y-Lopez; E F Farias
Journal:  Oncogene       Date:  2010-05-10       Impact factor: 9.867

Review 2.  Sorting out the functional role(s) of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in cell proliferation and cancer.

Authors:  Jeffrey M Peters; Frank J Gonzalez
Journal:  Biochim Biophys Acta       Date:  2009-06-06

Review 3.  Retinoids: novel immunomodulators and tumour-suppressive agents?

Authors:  M R Carratù; C Marasco; G Mangialardi; A Vacca
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

Review 4.  Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.

Authors:  Robert D Bruno; Vincent C O Njar
Journal:  Bioorg Med Chem       Date:  2007-05-23       Impact factor: 3.641

5.  Association study between novel CYP26 polymorphisms and the risk of betel quid-related malignant oral disorders.

Authors:  Shyh-Jong Wu; Yun-Ju Chen; Tien-Yu Shieh; Chun-Ming Chen; Yen-Yun Wang; Kun-Tsung Lee; Yueh-Ming Lin; Pei-Hsuan Chien; Ping-Ho Chen
Journal:  ScientificWorldJournal       Date:  2015-03-09

6.  Ligand activation of peroxisome proliferator-activated receptor-beta/delta inhibits cell proliferation in human HaCaT keratinocytes.

Authors:  Michael G Borland; Jennifer E Foreman; Elizabeth E Girroir; Reza Zolfaghari; Arun K Sharma; Shantu Amin; Frank J Gonzalez; A Catharine Ross; Jeffrey M Peters
Journal:  Mol Pharmacol       Date:  2008-08-07       Impact factor: 4.054

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.